225 related articles for article (PubMed ID: 31937234)
1. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.
Sahoo P; Yang X; Abler D; Maestrini D; Adhikarla V; Frankhouser D; Cho H; Machuca V; Wang D; Barish M; Gutova M; Branciamore S; Brown CE; Rockne RC
J R Soc Interface; 2020 Jan; 17(162):20190734. PubMed ID: 31937234
[TBL] [Abstract][Full Text] [Related]
2. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it.
Yin X; He L; Guo Z
Immunology; 2023 Aug; 169(4):400-411. PubMed ID: 36942414
[TBL] [Abstract][Full Text] [Related]
3. Exhaustion of CAR T cells: potential causes and solutions.
Kouro T; Himuro H; Sasada T
J Transl Med; 2022 May; 20(1):239. PubMed ID: 35606821
[TBL] [Abstract][Full Text] [Related]
4. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
5. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
6. The persistence and antitumor efficacy of CAR-T cells are modulated by tonic signaling within the CDR.
Zhou J; Shi F; Luo X; Lei B; Shi Z; Huang C; Zhang Y; Li X; Wang H; Li XY; He X
Int Immunopharmacol; 2024 Jan; 126():111239. PubMed ID: 37979453
[TBL] [Abstract][Full Text] [Related]
7. The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy.
Kimmel GJ; Locke FL; Altrock PM
Proc Biol Sci; 2021 Mar; 288(1947):20210229. PubMed ID: 33757357
[TBL] [Abstract][Full Text] [Related]
8.
Sun C; Li D; Wang Z
Immunotherapy; 2024 Mar; 16(5):331-340. PubMed ID: 38264838
[TBL] [Abstract][Full Text] [Related]
9. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
10. Data driven model discovery and interpretation for CAR T-cell killing using sparse identification and latent variables.
Brummer AB; Xella A; Woodall R; Adhikarla V; Cho H; Gutova M; Brown CE; Rockne RC
Front Immunol; 2023; 14():1115536. PubMed ID: 37256133
[TBL] [Abstract][Full Text] [Related]
11. Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion.
Lamarche C; Ward-Hartstonge K; Mi T; Lin DTS; Huang Q; Brown A; Edwards K; Novakovsky GE; Qi CN; Kobor MS; Zebley CC; Weber EW; Mackall CL; Levings MK
Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2219086120. PubMed ID: 36972454
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy.
Brummer AB; Yang X; Ma E; Gutova M; Brown CE; Rockne RC
PLoS Comput Biol; 2022 Jan; 18(1):e1009504. PubMed ID: 35081104
[TBL] [Abstract][Full Text] [Related]
13. Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology.
Qi T; McGrath K; Ranganathan R; Dotti G; Cao Y
Adv Drug Deliv Rev; 2022 Sep; 188():114421. PubMed ID: 35809868
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
15. Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction.
Jiang P; Zhang Z; Hu Y; Liang Z; Han Y; Li X; Zeng X; Zhang H; Zhu M; Dong J; Huang H; Qian P
Leukemia; 2022 Nov; 36(11):2656-2668. PubMed ID: 35962059
[TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptors for the Tumour Microenvironment.
Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
[TBL] [Abstract][Full Text] [Related]
17. CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.
Larson RC; Kann MC; Bailey SR; Haradhvala NJ; Llopis PM; Bouffard AA; Scarfó I; Leick MB; Grauwet K; Berger TR; Stewart K; Anekal PV; Jan M; Joung J; Schmidts A; Ouspenskaia T; Law T; Regev A; Getz G; Maus MV
Nature; 2022 Apr; 604(7906):563-570. PubMed ID: 35418687
[TBL] [Abstract][Full Text] [Related]
18. Modeling interaction of Glioma cells and CAR T-cells considering multiple CAR T-cells bindings.
Li R; Sahoo P; Wang D; Wang Q; Brown CE; Rockne RC; Cho H
Immunoinformatics (Amst); 2023 Mar; 9():. PubMed ID: 36875891
[TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
20. Engineering chimeric antigen receptor-T cells for cancer treatment.
Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]